Long non-coding RNA, steroid receptor RNA activator (SRA), induces tumor proliferation and invasion through the NOTCH pathway in cervical cancer cell lines

Eoh,Kyung Jin; Paek,Jiheum; Kim,Sang Wun; Kim,Hee Jung; Lee,Hye Yeon; Lee,Sang Kil; Kim,Young Tae

doi:10.3892/or.2017.6023

Long non-coding RNA, steroid receptor RNA activator (SRA), induces tumor proliferation and invasion through the NOTCH pathway in cervical cancer cell lines

Authors:
- Kyung Jin Eoh
- Jiheum Paek
- Sang Wun Kim
- Hee Jung Kim
- Hye Yeon Lee
- Sang Kil Lee
- Young Tae Kim
View Affiliations

Affiliations: Institute of Women's Life Medical Science, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seodaemun-gu, Seoul 03722, Republic of Korea, Departments of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Republic of Korea, Department of Anatomy, Yonsei University College of Medicine, Seodaemun-gu, Seoul 03722, Republic of Korea, Department of Internal Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul 03722, Republic of Korea
Published online on: October 11, 2017 https://doi.org/10.3892/or.2017.6023
Pages: 3481-3488
Copyright: © Eoh et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Contemporary research has focused on the function of long non-coding RNAs (lncRNAs) in carcinogenesis. However, the involvement of the lncRNA, steroid receptor RNA activator (SRA), in cervical carcinogenesis remains to be elucidated. In the present study, we investigated the bio-functional consequences of lncRNA SRA knockdown in vitro. To verify the role of lncRNA SRA in cell proliferation, migration, and invasion, lncRNA RNA interference was utilized to knock down lncRNA SRA expression in cervical cancer cell lines, resulting in our discovery that lncRNA SRA knockdown inhibited cell proliferation, cell migration and tumor invasion in the cervical cancer cell lines. Additionally, in vitro experiments using the lncRNA SRA-knockdown cervical cancer cell lines revealed that lncRNA SRA is a strong inducer and modulator of the expression of genes related to epithelial-mesenchymal transition and the NOTCH signaling pathway. In conclusion, our findings demonstrated that lncRNA SRA is highly correlated with cancer progression and cervical cancer cell proliferation and migration. Furthermore, these results indicate that lncRNA SRA may be a potential therapeutic target and prognostic marker for cervical malignancy.

View Figures

View References

1	Kodama J, Seki N, Masahiro S, Kusumoto T, Nakamura K, Hongo A and Hiramatsu Y: Prognostic factors in stage IB-IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy. J Surg Oncol. 101:413–417. 2010.PubMed/NCBI
2	Noordhuis MG, Fehrmann RS, Wisman GB, Nijhuis ER, van Zanden JJ, Moerland PD, Ver Loren van Themaat E, Volders HH, Kok M, ten Hoor KA, et al: Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res. 17:1317–1330. 2011. View Article : Google Scholar : PubMed/NCBI
3	Perez DS, Hoage TR, Pritchett JR, Ducharme-Smith AL, Halling ML, Ganapathiraju SC, Streng PS and Smith DI: Long, abundantly expressed non-coding transcripts are altered in cancer. Hum Mol Genet. 17:642–655. 2008. View Article : Google Scholar : PubMed/NCBI
4	Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, et al: lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 477:295–300. 2011. View Article : Google Scholar : PubMed/NCBI
5	Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E, et al: Functional demarcation of active and silent chromatin domains in human HOX loci by non-coding RNAs. Cell. 129:1311–1323. 2007. View Article : Google Scholar : PubMed/NCBI
6	Ponting CP, Oliver PL and Reik W: Evolution and functions of long non-coding RNAs. Cell. 136:629–641. 2009. View Article : Google Scholar : PubMed/NCBI
7	Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, Horlings HM, Shah N, Umbricht C, Wang P, et al: Extensive and coordinated transcription of non-coding RNAs within cell-cycle promoters. Nat Genet. 43:621–629. 2011. View Article : Google Scholar : PubMed/NCBI
8	Liu C, Wu HT, Zhu N, Shi YN, Liu Z, Ao BX, Liao DF, Zheng XL and Qin L: Steroid receptor RNA activator: Biologic function and role in disease. Clin Chim Acta. 459:137–146. 2016. View Article : Google Scholar : PubMed/NCBI
9	Yan R, Wang K, Peng R, Wang S, Cao J, Wang P and Song C: Genetic variants in lncRNA SRA and risk of breast cancer. Oncotarget. 7:22486–22496. 2016. View Article : Google Scholar : PubMed/NCBI
10	Hussein-Fikret S and Fuller PJ: Expression of nuclear receptor coregulators in ovarian stromal and epithelial tumours. Mol Cell Endocrinol. 229:149–160. 2005. View Article : Google Scholar : PubMed/NCBI
11	Cooper C, Guo J, Yan Y, Chooniedass-Kothari S, Hube F, Hamedani MK, Murphy LC, Myal Y and Leygue E: Increasing the relative expression of endogenous non-coding steroid receptor RNA activator (SRA) in human breast cancer cells using modified oligonucleotides. Nucleic Acids Res. 37:4518–4531. 2009. View Article : Google Scholar : PubMed/NCBI
12	Colley SM and Leedman PJ: Steroid Receptor RNA Activator - A nuclear receptor coregulator with multiple partners: Insights and challenges. Biochimie. 93:1966–1972. 2011. View Article : Google Scholar : PubMed/NCBI
13	Cooper C, Vincett D, Yan Y, Hamedani MK, Myal Y and Leygue E: Steroid Receptor RNA Activator bi-faceted genetic system: Heads or Tails? Biochimie. 93:1973–1980. 2011. View Article : Google Scholar : PubMed/NCBI
14	Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, et al: RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group): The transcriptional landscape of the mammalian genome. Science. 309:1559–1563. 2005. View Article : Google Scholar : PubMed/NCBI
15	Morris KV and Vogt PK: Long antisense non-coding RNAs and their role in transcription and oncogenesis. Cell Cycle. 9:2544–2547. 2010. View Article : Google Scholar : PubMed/NCBI
16	Dinger ME, Amaral PP, Mercer TR, Pang KC, Bruce SJ, Gardiner BB, Askarian-Amiri ME, Ru K, Soldà G, Simons C, et al: Long non-coding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res. 18:1433–1445. 2008. View Article : Google Scholar : PubMed/NCBI
17	Hall PA and Russell SH: New perspectives on neoplasia and the RNA world. Hematol Oncol. 23:49–53. 2005. View Article : Google Scholar : PubMed/NCBI
18	Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
19	Kim HJ, Lee DW, Yim GW, Nam EJ, Kim S, Kim SW and Kim YT: Long non-coding RNA HOTAIR is associated with human cervical cancer progression. Int J Oncol. 46:521–530. 2015. View Article : Google Scholar : PubMed/NCBI
20	Kim HJ, Eoh KJ, Kim LK, Nam EJ, Yoon SO, Kim KH, Lee JK, Kim SW and Kim YT: The long non-coding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer. Oncotarget. 7:83001–83016. 2016. View Article : Google Scholar : PubMed/NCBI
21	Curran S and Murray GI: Matrix metalloproteinases: Molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 36:1621–1630. 2000. View Article : Google Scholar : PubMed/NCBI
22	Biewenga P, van der Velden J, Mol BW, Stalpers LJ, Schilthuis MS, van der Steeg JW, Burger MP and Buist MR: Prognostic model for survival in patients with early stage cervical cancer. Cancer. 117:768–776. 2011. View Article : Google Scholar : PubMed/NCBI
23	Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology. 69 Suppl 3:S4–S10. 2005. View Article : Google Scholar
24	Burger RA: Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies. J Gynecol Oncol. 21:3–11. 2010. View Article : Google Scholar : PubMed/NCBI
25	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
26	Ramis-Conde I, Chaplain MA, Anderson AR and Drasdo D: Multi-scale modelling of cancer cell intravasation: The role of cadherins in metastasis. Phys Biol. 6:0160082009. View Article : Google Scholar : PubMed/NCBI
27	Morin PJ: beta-catenin signaling and cancer. BioEssays. 21:1021–1030. 1999. View Article : Google Scholar : PubMed/NCBI
28	Martin TA, Goyal A, Watkins G and Jiang WG: Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol. 12:488–496. 2005. View Article : Google Scholar : PubMed/NCBI
29	Calaf GM, Balajee AS, Montalvo-Villagra MT, Leon M, Daniela NM, Alvarez RG, Roy D, Narayan G and Abarca-Quinones J: Vimentin and Notch as biomarkers for breast cancer progression. Oncol Lett. 7:721–727. 2014. View Article : Google Scholar : PubMed/NCBI
30	Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: Cell fate control and signal integration in development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
31	Timmerman LA, Grego-Bessa J, Raya A, Bertrán E, Pérez-Pomares JM, Díez J, Aranda S, Palomo S, McCormick F, Izpisúa-Belmonte JC, et al: Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 18:99–115. 2004. View Article : Google Scholar : PubMed/NCBI
32	Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y and Sarkar FH: Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 66:2778–2784. 2006. View Article : Google Scholar : PubMed/NCBI
33	Nair P, Somasundaram K and Krishna S: Activated Notch1 inhibits p53-induced apoptosis and sustains transformation by human papillomavirus type 16 E6 and E7 oncogenes through a PI3K-PKB/Akt-dependent pathway. J Virol. 77:7106–7112. 2003. View Article : Google Scholar : PubMed/NCBI
34	Masuda S, Kumano K, Shimizu K, Imai Y, Kurokawa M, Ogawa S, Miyagishi M, Taira K, Hirai H and Chiba S: Notch1 oncoprotein antagonizes TGF-beta/Smad-mediated cell growth suppression via sequestration of co-activator p300. Cancer Sci. 96:274–282. 2005. View Article : Google Scholar : PubMed/NCBI
35	Klinakis A, Szabolcs M, Politi K, Kiaris H, Artavanis-Tsakonas S and Efstratiadis A: Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci USA. 103:9262–9267. 2006. View Article : Google Scholar : PubMed/NCBI
36	Liu ZH, Dai XM and Du B: Hes1: A key role in stemness, metastasis and multidrug resistance. Cancer Biol Ther. 16:353–359. 2015. View Article : Google Scholar : PubMed/NCBI
37	Oswald F, Täuber B, Dobner T, Bourteele S, Kostezka U, Adler G, Liptay S and Schmid RM: p300 acts as a transcriptional co-activator for mammalian Notch-1. Mol Cell Biol. 21:7761–7774. 2001. View Article : Google Scholar : PubMed/NCBI